Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies-Reference-Cited by-同舟云学术

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

Published:2020-07-03 Issue:12 Volume:34 Page:2830-2838
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Strober B.¹²^ORCID,Menter A.³,Leonardi C.⁴,Gordon K.⁵,Lambert J.⁶,Puig L.⁷^ORCID,Photowala H.⁸,Longcore M.⁸,Zhan T.⁸,Foley P.⁹

Affiliation:

1. Yale University New Haven CT USA

2. Central Connecticut Dermatology Research Cromwell CT USA

3. Baylor Scott and White Dallas TX USA

4. Central Dermatology Richmond Heights MO USA

5. Medical College of Wisconsin Milwaukee WI USA

6. Ghent University Ghent Belgium

7. Hospital de la Santa Creu i Sant Pau Barcelona Spain

8. AbbVie, Inc. North Chicago IL USA

9. St. Vincent’s Hospital Melbourne Probity Medical Research Skin Health Institute The University of Melbourne Melbourne VIC Australia

Funder

AbbVie

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16521

Reference33 articles.

1. The immunogenetics of Psoriasis: A comprehensive review

2. Psoriasis causes as much disability as other major medical diseases

3. Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity

4. The effect of weight on the efficacy of biologic therapy in patients with psoriasis

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis;JAMA Dermatology;2024-08-01

2. Determining the Treatment Strategy for Refractory Ulcerative Colitis Using Prostaglandin E-major Urinary Metabolite (PGE-MUM) Measurement;Cureus;2024-07-16

3. Sequencing of Targeted Therapy in Psoriasis: Does it Matter?;American Journal of Clinical Dermatology;2024-07-13

4. Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis;Journal of the European Academy of Dermatology and Venereology;2024-03-20

5. Therapy of moderate-to-severe plaque psoriasis;Meditsinskiy sovet = Medical Council;2024-03-06